THANK YOU FOR SUBSCRIBING
Pharma Tech Outlook Weekly Brief
Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Pharma Tech Outlook
Mr. John Rim, President & CEOSamsung Biologics offers a fully integrated service at a single site to help bring a drug from early development to clinical and commercial manufacturing. This full-service offering enables clients to bring their transformational biologics to market with utmost agility, cost-effectiveness, and flexibility. “We are able to serve our clients faster and better by offering them a one-stop service,” says John Rim, the President and CEO of Samsung Biologics. With its extensive and streamlined project management expertise, the company ensures a f lexible and scalable drug development process at an expedited timeline. For example, recently, Samsung Biologics launched its development platforms “S-Cellerate to IND” and “S-Cellerate to BLA”, offering an expedited drug development timeline for standard monoclonal antibodies. With S-Cellerate, clients are able to reach IND filings in as fast as nine months.
With innovation in its DNA, Samsung Biologics is constantly bringing in new cutting-edge technologies—bioprocessing, automation, and digitalization—to improve productivity and efficiency. This assists in real-time monitoring, cutting down cost and time to market, and expediting the drug development and manufacturing process. “Ultimately, we leverage digitalization to optimize the client experience and ensure greater client satisfaction through these innovative business practices,” states Mr. Rim. Further, Samsung Biologics is continuously pushing the boundaries to redefine biologics development and manufacturing. The company offers streamlined processes with faster timelines, multi-scale solutions enabling maximum flexibility, a high throughput filling with quality assurance, and experienced global regulatory support.
In all of our expansion efforts, client satisfaction has and always will be our primary focus, and we are reshaping the expectations of our capacity and capabilities in the industry
Company
Samsung Biologics
Management
Mr. John Rim, President & CEO
Description
With proven regulatory approvals, the largest single-site capacity, and the fastest throughput, Samsung Biologics is an award-winning partner of choice and is uniquely able to provide seamless offerings from development, manufacturing to laboratory testing services at every stage for biopharmaceutical products while meeting the evolving needs of the global healthcare industry. By continuously innovating their People, Process, and Portfolio, they will fulfill their mission to become the most trusted partner to our clients, working together to achieve a "Better Life" for humanity through biomedicines
The Terra Carta Seal, launched at COP26 by His Majesty King Charles III when he was Prince of Wales, recognises global companies that are driving innovation and demonstrating their commitment to, and momentum towards, the creation of genuinely sustainable markets. It is being awarded to companies whose ambitions are aligned with those of the Terra Carta, a recovery plan for Nature, People and Planet, launched in January 2021.
Samsung Biologics affirmed its commitment to achieving net zero greenhouse gas emissions across its direct operations and supply chain by 2050 or earlier as part of its global response to climate change.
Due to the complex nature of bioprocessing, the company’s environmental management strategy outlines a number of core activities to reduce emissions, including process energy optimization, transitioning to renewable energy by investing in solar panels and utilizing external resources, converting to zero emission vehicles, and minimizing the use of disposables in the manufacturing process through waste management and recycling.
Samsung Biologics is also working to drive successful decarbonization by committing to 100% renewable power through the Climate Group’s RE100 initiative and adopting the recommendations of the Task Force on Climate-Related Financial Disclosures (TCFD) in reporting its climate actions progress.
John Rim, CEO and President, Samsung Biologics said: “We are honoured to be recognized with the Terra Carta Seal by the Sustainable Markets Initiative for Samsung Biologics’ contribution in working alongside our industry peers for this global effort. Healthcare is at a pivotal moment and through our collaborative efforts, we can contribute to shaping climate-resilient practices to influence and help shape policy across the pharmaceutical and healthcare sectors.”
Brian Moynihan, Co-Chair, Sustainable Markets Initiative said: “The SMI brings CEOs together to work on the shared goals of accelerating our transition to a sustainable future. I congratulate those organizations recognized with the 2022 Terra Carta Seal and thank them for their commitment to sustainable markets.”
The Terra Carta Seal acknowledges that each industry faces unique challenges in its transition to a sustainable future and they are all at different stages of their journey. And all industries and companies must be supported as they take steps in a more positive direction. At the same time, an accelerated pace is required if we are to achieve a 1.5-degree target, protect and restore biodiversity and benefit the lives and livelihoods of current and future generations.
Alongside its work to eliminate carbon emissions from its own operations, Samsung Biologics is engaging its suppliers as part of a broader initiative by the Supply Chains Working Group within the Sustainable Markets Initiative’s Health Systems Task Force to reduce direct emissions and identify carbon reduction options with the goal of reaching net zero in its supply chain. Last month, the Task Force announced joint action at COP27 to achieve near-term emissions reduction targets and published commitments to decarbonize through a series of whitepapers outlining practical recommendations and scalable actions for health systems stakeholders.
Sir Jony Ive and his creative team at LoveFrom created a physical and animated seal engineered with paper that is both simple and beautifully crafted. The design combines a host of natural references including oak leaves, fern, magnolia and honeybees and intricate patterns both in nature and in the arts, creating a visual celebration which reflects the power of and reverence for nature that is at the heart of the Terra Carta.
For more details and continuous updates on sustainability activities, please visit the Samsung Biologics’ Sustainability page.